# Evaluation of Miricorilant on Liver Fat in Patients With MASLD

> **NCT06947304** · PHASE1 · RECRUITING · sponsor: **Corcept Therapeutics** · enrollment: 8 (estimated)

## Conditions studied

- Nonalcoholic Steatohepatitis (NASH)
- Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- Non-alcoholic Fatty Liver Disease (NAFLD)

## Interventions

- **DRUG:** Miricorilant

## Key facts

- **NCT ID:** NCT06947304
- **Lead sponsor:** Corcept Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-22
- **Primary completion:** 2026-05
- **Final completion:** 2026-05
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2026-02-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06947304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06947304, "Evaluation of Miricorilant on Liver Fat in Patients With MASLD". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06947304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*